You are here
L2 DIAGNOSTICS LLC
UEI: GKA7VH5LFR25
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response
Amount: $453,442.00Abstract Despite the advent of biological therapiesglucocorticoidsGCsremain the most widely prescribed medicines for the management of inflammatory diseases such as lupusasthmamultiple sclerosisand rh ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus
Amount: $225,000.00ABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switche ...
STTRPhase I2018Department of Health and Human Services National Institutes of Health -
Development of a Point of Care Diagnostic Screening test for Kawasaki disease
Amount: $224,963.00ABSTRACT Kawasaki DiseaseKDis a febrile childhood vasculitis with potentially catastrophic clinical outcomesUntreatedone in five children develop coronary artery aneurysms causing significant morbidit ...
STTRPhase I2018Department of Health and Human Services National Institutes of Health -
A Rapid Low Cost Point of Care Diagnostic for detection of Zika virus RNA
Amount: $225,000.00ABSTRACT Zika virus ZIKV has rapidly emerged and spread through South and Central America the Caribbean and Puerto Rico since its last outbreak in Micronesia in Transmitted by the mosquito A ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Validation of a Diagnostic Test for Borrelia miyamotoi
Amount: $574,217.00ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis path ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy
Amount: $299,754.00Checkpoint inhibitor CPI therapy has transformed treatment of solid tumors Clinical responses in the range of with prolonged survival have been reported for tumors such as malignant melan ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTRATE CANCER RADIOTHERAPY
Amount: $1,996,011.00The overall objective of this project is to advance the development of a clinically usefully multiplex assay todetect biomarkers of radio sensitivity that will identify subsets of prostate cancer pati ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma
Amount: $298,959.00DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection
Amount: $300,000.00DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial t ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy
Amount: $1,481,590.00Abstract The long term product goal of this project is a small molecule rheumatoid arthritis RA therapeutic which acts by reducing the inflammatory response triggered by the pro inflammatory cytokin ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health
